The rapid emergence and re-emergence of viral pathogens—exemplified by outbreaks of influenza, Ebola, Zika, and, most recently, SARS-CoV-2—underscore the ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

AI in Cancer Drug Discovery could prove paradigm shifting, but what challenges does it present? And how can they be avoided?

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

Transparent expectation-setting and addressing potential disappointments can foster safety, reduce anxiety, and promote ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

Researchers at NYU Tandon School of Engineering have developed a new method for creating microscopic drug delivery capsules ...

Medpace beats Q2 2025 earnings, raises FY guidance, showcasing strong biotech demand. Click here to read an analysis of MEDP ...

Amid a season of regulatory and scientific advances, experts reveal a culture of data hoarding among cell and gene therapy ...